This phase 2 trial is testing an experimental drug called TVB-2640 in 18 people with a specific type of advanced lung cancer that has a KRAS mutation and has not responded to standard treatments. Participants take the drug as a pill once daily for 8 weeks. The study aims to see i…
Phase 2 • Sponsor: David E Gerber • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC